Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MONITOR
August 23, 2004
- NEW PRODUCTS
August 23, 2004
- Meet the Leaders (35)
August 23, 2004
- Precautions Revised for 4 Drugs Including Clarithromycin
August 23, 2004
- Daiichi to Return to Track of Growth via Structural Reform
August 23, 2004
- REGULATORY NEWS IN BRIEF
August 23, 2004
- Aiming at Sales of \120 Bil. in 2010: Mr Crenshaw of Eli Lilly Japan
August 23, 2004
- NHO Plans to Improve Domestic Clinical Trials
August 23, 2004
- Eisai to Triple Production of Aricept, Pariet at Kashima Plant
August 23, 2004
- BULLETIN
August 23, 2004
- Mr Komine of MPC Stresses Medicoeconomic Benefits of Zione
August 23, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 23, 2004
- DIAGNOSTIC NEWS IN BRIEF
August 23, 2004
- 1st Qtr Business Results
August 23, 2004
- Chugai to Strengthen Antibody Drug Business by Transferring OTC Business to Lion
August 23, 2004
- OTC NEWS IN BRIEF
August 23, 2004
- BUSINESS NEWS IN BRIEF
August 23, 2004
- Korosho Calls For Proper Use of Cypher Stents, Ticlopidine
August 23, 2004
- WEB SITE NEWS
August 23, 2004
- Terumo Ties Up with Spenser Technologies of the US in Diagnosis of Cerebral, Cardiac Diseases
August 23, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…